Logo En IconLogo Mark IconIcelandic Intellectual Property Office
Plus Black IconMortgagePlus Black IconLicensePlus Black IconRevocationPlus Black IconReissuePlus Black IconCorrected translationPlus Black IconSPC

EP3400065

CNP örvar með stýrða losun með minnkaðar aukaverkanir

  • Status:
    EP einkaleyfi í gildi á Íslandi
  • EP appl. date:
    5.1.2017
  • EP published:
    17.12.2025
  • EP application number:
    17700906.5
  • Max expiry date:
    4.1.2037
  • Expiry date:
    4.1.2027
  • Next due date:
    31.1.2027
  • Title in English:
    CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS
  • Language of the patent:
    English

Timeline

Today
5.1.2017EP application
17.12.2025EP Publication
30.1.2026Translation submitted
11.2.2026Registration published
4.1.2027Expires

Owner

  • Name:
    Ascendis Pharma Growth Disorders A/S
  • Address:
    Tuborg Boulevard 12, 2900 Hellerup, DK

Inventor

  • Name:
    SPROGØE, Kennett
  • Address:
    2900 Hellerup, DK
  • Name:
    RAU, Harald
  • Address:
    69120 Heidelberg, DE
  • Name:
    CLEEMANN, Felix
  • Address:
    69120 Heidelberg, DE
  • Name:
    HERSEL, Ulrich
  • Address:
    69120 Heidelberg, DE
  • Name:
    RASMUSSEN, Caroline Elisabeth
  • Address:
    2900 Hellerup, DK

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113, Reykjavík,

Priority

  • Number:
    16150635
  • Date:
    8.1.2016
  • Country:
    EP
  • Number:
    16179293
  • Date:
    13.7.2016
  • Country:
    EP
  • Number:
    16191482
  • Date:
    29.9.2016
  • Country:
    EP

Classification

  • Categories:
    A61P 19/08, A61K 47/60, A61K 47/68

Annual fees

Number

Paid

Expires

Payer

Number: 10

Paid: 26.1.2026

Expires: 4.1.2027

Payer: Árnason Faktor ehf.

Upload documents